Possible sites of therapeutic action in restless legs syndrome: Focus on dopamine and α 2δ ligands

European Neurology

Volumn 66, Issue 1, 2011, Pages 18-29

  Thorpe, Andrew J ^a   Clair, Andrew ^a   Hochman, Shawn ^b   Clemens, Stefan ^c  

^a PFIZER INC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Adenosine A 2A receptor; Dopamine; Iron; Opioids; Restless legs syndrome; Voltage gated calcium channel 2 ligands

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CABERGOLINE; CYCLIC AMP; DELTA OPIATE RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; GABAPENTIN ENACARBIL; IRON; IRON DEXTRAN; LEVODOPA; LISURIDE; METHADONE; OPIATE; OPIATE RECEPTOR AFFECTING AGENT; OXYCODONE; PERGOLIDE; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; SIGMA OPIATE RECEPTOR; TRAMADOL;

ANAPHYLAXIS; COMPULSIVE PERSONALITY DISORDER; CONSTIPATION; DISEASE ASSOCIATION; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; HEART MUSCLE FIBROSIS; HUMAN; IRON DEFICIENCY; IRON THERAPY; LUNG FIBROSIS; MOTOR NERVE; NAUSEA; NERVE CELL NETWORK; NEUROMODULATION; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; RESTLESS LEGS SYNDROME; REVIEW; SENSORY NERVE; SLEEP APNEA SYNDROME; SPINAL CORD FUNCTION; SYMPATHETIC TONE;

CALCIUM CHANNELS; DOPAMINE; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIGANDS; RECEPTORS, DOPAMINE D2; RECEPTORS, OPIOID; RECEPTORS, PURINERGIC P1; RESTLESS LEGS SYNDROME; SPINAL CORD;

EID: 79959547276     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000328431     Document Type: Review

References (158)

1. García-Borreguero D, Egatz R, Winkelmann J, Berger K: Epidemiology of restless legs syndrome: The current status. Sleep Med Rev 2006; 10: 153-167. (Pubitemid 43817594)
2. Allen RP, Stillman P, Myers AJ: Physiciandiagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med 2010; 11: 31-37.
3. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J; Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health, International Restless Legs Syndrome Study Group: Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119. (Pubitemid 36527231)
4. Willis T: Of diseases of the brain and genus nervosum; in Willis T: The London Practice of Physick. London, Bassett and Crooke, 1685.
5. Ekbom KA: Asthenia crurum pasasthetica (irritable legs). Acta Med Scand 1944; 118: 197-209.
6. Ekbom KA: Restless legs syndrome. Acta Med Scand 1945; 158(suppl):4-122.
7. García-Borreguero D, Odin P, Schwarz C: Restless legs syndrome: An overview of the current understanding and management. Acta Neurol Scand 2004; 109: 303-317. (Pubitemid 38580897)
8. Clemens S, Rye D, Hochman S: Restless legs syndrome: Revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006; 67: 125-130. (Pubitemid 44305475)
9. Trenkwalder C, Paulus W: Restless legs syndrome: Pathophysiology, clinical presentation and management. Nat Rev Neurol 2010; 6: 337-346.
10. Allen RP, Earley CJ: The role of iron in restless legs syndrome. Mov Disord 2007; 22(suppl 18):S440-S448.
11. Unger EL, Earley CJ, Beard JL: Diurnal cycle influences peripheral and brain iron levels in mice. J Appl Physiol 2009; 106: 187-193.
12. Connor JR: Pathophysiology of restless legs syndrome: Evidence for iron involvement. Curr Neurol Neurosci Rep 2008; 8: 162-166. (Pubitemid 351460250)
13. Trenkwalder C, Hoegl B, Winkelmann J: Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol 2009; 256: 539-553.
14. Ondo WG, He Y, Rajasekaran S, Le WD: Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: A possible model for restless legs syndrome. Mov Disord 2000; 15: 154-158. (Pubitemid 30038003)
15. Allen RP: Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome. Am J Med 2007; 120(suppl 1):S13-S21. (Pubitemid 46014145)
16. Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, Earley CJ: Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009; 132: 2403-2412.
17. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C: Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice. Mov Disord 2008; 23: 2267-2302.
18. Manconi M, Ferri R, Zucconi M, Oldani A, Fantini ML, Castronovo V, Ferini-Strambi L: First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med 2007; 8: 491-497. (Pubitemid 46991574)
19. Happe S, Trenkwalder C: Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 2004; 18: 27-36. (Pubitemid 38197757)
20. Kvernmo T, Härtter S, Burger E: A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-1078. (Pubitemid 44374749)
21. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D 2 -like receptor and 1 /α 2 -adrenoceptor. J Pharmacol Exp Ther 2002; 303: 805-814. (Pubitemid 35231257)
22. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H: The in vitro receptor profile of rotigotine: A new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 73-86.
23. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH: Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007; 68: 301-303. (Pubitemid 46148346)
24. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB: Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969-973. (Pubitemid 44036299)
25. Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR: A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000; 43: 70-75. (Pubitemid 30114095)
26. Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A: Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, doubleblind, placebo-controlled study. Sleep Med 2009; 10: 973-975.
27. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD: A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004; 43: 663-670. (Pubitemid 38401881)
28. Earley CJ, Heckler D, Allen RP: Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep Med 2005; 6: 301-305. (Pubitemid 40867819)
29. Ondo WG: Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med 2010; 11: 494-496.
30. Earley CJ: The importance of oral iron therapy in restless legs syndrome. Sleep Med 2009; 10: 945-946.
31. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, Kavey N: Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993; 16: 327-332. (Pubitemid 23176289)
32. Lauerma H, Markkula J: Treatment of restless legs syndrome with tramadol: An open study. J Clin Psychiatry 1999; 60: 241-244. (Pubitemid 29193922)
33. Ondo WG: Methadone for refractory restless legs syndrome. Mov Disord 2005; 20: 345-348. (Pubitemid 40613296)
34. Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, Rye DB; Medical Advisory Board of the Restless Legs Syndrome Foundation: An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004; 79: 916-922.
35. Vignatelli L, Billiard M, Clarenbach P, Garcia-Borreguero D, Kaynak D, Liesiene V, Trenkwalder C, Montagna P; EFNS Task Force: EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006; 13: 1049-1065. (Pubitemid 44434310)
36. Vetrugno R, La Morgia C, D'Angelo R, Loi D, Provini F, Plazzi G, Montagna P: Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 2007; 22: 424-427. (Pubitemid 46569705)
37. Yue HJ, Guilleminault C: Opioid medication and sleep-disordered breathing. Med Clin North Am 2010; 94: 435-446.
38. Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M, Sharma R, Hening W, Li L: Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16: 1105-1109. (Pubitemid 36041223)
39. Muller CE, Ferré S: Blocking striatal adenosine A2A receptors: A new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov 2007; 2: 1-21. (Pubitemid 46729088)
40. Quiroz C, Pearson V, Gulyani S, Allen R, Earley C, Ferré S: Up-regulation of striatal adenosine A 2A receptors with iron deficiency in rats. Effects on locomotion and cortico-striatal neurotransmission. Exp Neurol 2010; 224: 292-298.
41. García-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G: Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology 2002; 59: 1573-1579. (Pubitemid 35387065)
42. Agarwal P, Griffith A, Costantino HR, Vaish N: Gabapentin enacarbil -clinical efficacy in restless legs syndrome. Neuropsychiatr Dis Treat 2010; 6: 151-158.
43. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP052 Study Group: Randomized, double-blind, placebocontrolled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009; 72: 439-446.
44. Kushida CA, Walters AS, Becker P, Thein SG, Perkins AT, Roth T, Canafax D, Barrett RW; XP021 Study Group: A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009; 32: 159-168.
45. Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP045 Study Group: Gabapentin enacarbil in restless legs syndrome: A phase 2b, 2-week, randomized, double-blind, placebocontrolled trial. Clin Neuropharmacol 2009; 32: 311-320.
46. Merlino G, Serafini A, Lorenzut S, Sommaro M, Gigli GL, Valente M: Gabapentin enacarbil in restless legs syndrome. Drugs Today (Barc) 2010; 46: 3-11.
47. Sommer M, Bachmann CG, Liebetanz KM, Schindehütte J, Tings T, Paulus W: Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007; 115: 347-350. (Pubitemid 46699434)
48. García-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, Fernandez C: Treatment of restless legs syndrome with pregabalin: A double-blind, placebo-controlled study. Neurology 2010; 74: 1897-1904.
49. Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, García-Borreguero D, Miceli J: A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010; 11: 512-519.
50. Bogan RK, Bornemann MA, Kushida CA, Trǎn PV, Barrett RW; XP060 Study Group: Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: A randomized controlled study. Mayo Clin Proc 2010; 85: 512-521.
51. Hochman S: Spinal cord. Current Biology 2007; 17:R950-R955. (Pubitemid 350088483)
52. Kuhar MJ, Couceyro PR, Lambert PD: Catecholamines; in Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds): Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia, PA, Lippincott Williams & Wilkins, 1999, ed 3, pp 243-262.
53. Holstege JC, Van Dijken H, Buijs RM, Goedknegt H, Gosens T, Bongers CM: Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal cord. J Comp Neurol 1996; 376: 631-652. (Pubitemid 27009845)
54. Zhu H, Clemens S, Sawchuk M, Hochman S: Expression and distribution of all dopamine receptor subtypes (D 1 -D 5 ) in the mouse lumbar spinal cord: A real-time polymerase chain reaction and non-autoradiographic in situ hybridization study. Neuroscience 2007; 149: 885-897. (Pubitemid 350122885)
55. Cavallotti C, Frati A, Cavallotti D, Tranquilli Leali FM: Dopaminergic receptors in rat dura mater: Pharmacological characteristics. Clin Exp Pharmacol Physiol 2004; 31: 190-194. (Pubitemid 38338718)
56. van Dijken H, Dijk J, Voom P, Holstege JC: Localization of dopamine D2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization. Eur J Neurosci 1996; 8: 621-628.
57. Levant B, McCarson KE: D 3 dopamine receptors in rat spinal cord: Implications for sensory and motor function. Neurosci Lett 2001; 303: 9-12. (Pubitemid 32285455)
58. Matsumoto M, Hidaka K, Akiho H, Tada S, Okada M, Yamaguchi T: Low stringency hybridization study of the dopamine D4 receptor revealed D4-like mRNA distribution of the orphan seven-transmembrane receptor, APJ, in human brain. Neurosci Lett 1996; 219: 119-122. (Pubitemid 26396329)
59. Wamsley JK, Gehlert DR, Filloux FM, Dawson TM: Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain. J Chem Neuroanat 1989; 2: 119-137. (Pubitemid 19157683)
60. Barraud Q, Obeid I, Aubert I, Barriere G, Contamin H, McGuire S, Ravenscroft P, Porras G, Tison F, Bezard E, Ghorayeb I: Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate. PLoS One 2010; 5:e13306.
61. Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland LJ: Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007; 156(suppl 1):S13-S21. (Pubitemid 46797839)
62. Paulus W, Dowling P, Rijsman R, Stiasny-Kolster K, Trenkwalder C, de Weerd A: Pathophysiological concepts of restless legs syndrome. Mov Disord 2007; 22: 1451-1456. (Pubitemid 47280631)
63. Skagerberg G, Lindvall O: Organization of diencephalic dopamine neurones projecting to the spinal cord in the rat. Brain Res 1985; 342: 340-351. (Pubitemid 16241913)
64. Qu S, Ondo WG, Zhang X, Xie WJ, Pan TH, Le WD: Projections of diencephalic dopamine neurons into the spinal cord in mice. Exp Brain Res 2006; 168: 152-156. (Pubitemid 41752820)
65. Carlsson A, Svennerholm L, Winblad B: Seasonal and circadian monoamine variations in human brains examined post mortem. Acta Psychiatr Scand Suppl 1980; 280: 75-85. (Pubitemid 11215806)
66. Qu S, Le W, Zhang X, Xie W, Zhang A, Ondo WG: Locomotion is increased in A11-lesioned mice with iron deprivation: A possible animal model for restless legs syndrome. J Neuropathol Exp Neurol 2007; 66: 383-388. (Pubitemid 46701320)
67. Earley CJ, Allen RP, Connor JR, Ferrucci L, Troncoso J: The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med 2009; 10: 1155-1157.
68. Hofman MA: The human circadian clock and aging. Chronobiol Int 2000; 17: 245-259. (Pubitemid 30366505)
69. Weinert D: Age-dependent changes of the circadian system. Chronobiol Int 2000; 17: 261-283. (Pubitemid 30366506)
70. Earley CJ, Hyland K, Allen RP: Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006; 7: 263-268.
71. Clemens S, Sawchuk MA, Hochman S: Reversal of the circadian expression of tyrosine-hydroxylase but not nitric oxide synthase levels in the spinal cord of dopamine D 3 receptor knockout mice. Neuroscience 2005; 133: 353-357. (Pubitemid 40726203)
72. Taepavarapruk N, Taepavarapruk P, John J, Lai YY, Siegel JM, Phillips AG, McErlane SA, Soja PJ: State-dependent changes in glutamate, glycine, GABA, and dopamine levels in cat lumbar spinal cord. J Neurophysiol 2008; 100: 598-608.
73. Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett M: Periodic limb movements in sleep: State-dependent excitability of the spinal flexor reflex. Neurology 2000; 54: 1609-1616.
74. Trenkwalder C, Hening WA, Walters AS, Campbell SS, Rahman K, Chokroverty S: Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord 1999; 14: 102-110. (Pubitemid 29224683)
75. Xie GX, Jones K, Peroutka SJ, Palmer PP: Detection of mRNAs and alternatively spliced transcripts of dopamine receptors in rat peripheral sensory and sympathetic ganglia. Brain Res 1998; 785: 129-135. (Pubitemid 28194762)
76. Molokanova EA, Tamarova ZA: The effects of dopamine and serotonin on rat dorsal root ganglion neurons: An intracellular study. Neuroscience 1995; 65: 859-867.
77. Fleetwood-Walker SM, Hope PJ, Mitchell R: Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. J Physiol 1988; 399: 335-348.
78. Pappas SS, Behrouz B, Janis KL, Goudreau JL, Lookingland KJ: Lack of D2 receptor mediated regulation of dopamine synthesis in A 11 diencephalospinal neurons in male and female mice. Brain Res 2008; 1214: 1-10.
79. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, Gerfen CR, Westphal H, Fuchs S: A targeted mutation of the D 3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996; 93: 1945-1949. (Pubitemid 26079860)
80. Asico LD, Ladines C, Fuchs S, Accili D, Carey RM, Semeraro C, Pocchiari F, Felder RA, Eisner GM, Jose PA: Disruption of the dopamine D 3 receptor gene produces renin-dependent hypertension. J Clin Invest 1998; 102: 493-498. (Pubitemid 28376151)
81. Ondo WG, Zhao HR, Le WD: Animal models of restless legs syndrome. Sleep Med 2007; 8: 344-348. (Pubitemid 46706360)
82. Dowling P, Klinker F, Stadelmann C, Hasan K, Paulus W, Liebetanz D: Dopamine D3 receptor specifically modulates motor and sensory symptoms in iron-deficient mice. J Neurosci 2011; 31: 70-77.
83. Clemens S, Hochman S: Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D 3 receptor knock-out mice. J Neurosci 2004; 24: 11337-11345. (Pubitemid 39658269)
84. Charbit AR, Akerman S, Holland PR, Goadsby PJ: Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: An electrophysiological and immunohistochemical study. J Neurosci 2009; 29: 12532-12541.
85. Taniguchi W, Nakatsuka T, Miyazaki N, Yamada H, Takeda D, Fujita T, Kumamoto E, Yoshida M: In vivo patch-clamp analysis of dopaminergic antinociceptive actions on substantia gelatinosa neurons in the spinal cord. Pain 2011; 152: 95-105.
86. Connor M, Christie MD: Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol 1999; 26: 493-499. (Pubitemid 29309619)
87. Dougherty PM, Staats PS: Intrathecal drug therapy for chronic pain: From basic science to clinical practice. Anesthesiology 1999; 91: 1891-1918.
88. Williams JT, Christie MJ, Manzoni O: Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001; 81: 299-343. (Pubitemid 32096178)
89. George SR, Zastawny RL, Briones-Urbina R, Cheng R, Nguyen T, Heiber M, Kouvelas A, Chan AS, O'Dowd BF: Distinct distributions of mu, delta and kappa opioid receptor mRNA in rat brain. Biochem Biophys Res Commun 1994; 205: 1438-1444.
90. Ji RR, Zhang Q, Law PY, Low HH, Elde R, Hökfelt T: Expression ofμ-,δ -, and κ -opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci 1995; 15: 8156-8166.
91. Mansour A, Fox CA, Burke S, Meng F, Thompson RC, Akil H, Watson SJ: Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study. J Comp Neurol 1994; 350: 412-438. (Pubitemid 24356007)
92. Peckys D, Landwehrmeyer GB: Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: A 33 P in situ hybridization study. Neuroscience 1999; 88: 1093-1135. (Pubitemid 28546992)
93. Morinville A, Cahill CM, Aibak H, Rymar VV, Pradhan A, Hoffert C, Mennicken F, Stroh T, Sadikot AF, O'Donnell D, Clarke PB, Collier B, Henry JL, Vincent JP, Beaudet A: Morphine-induced changes in δ opioid receptor trafficking are linked to somatosensory processing in the rat spinal cord. J Neurosci 2004; 24: 5549-5559. (Pubitemid 38812637)
94. Gouardéres C, Cros J, Quirion R: Autoradiographic localization of mu, delta and kappa opioid receptor binding sites in rat and guinea pig spinal cord. Neuropeptides 1985; 6: 331-342. (Pubitemid 15021861)
95. Honda CN, Arvidsson U: Immunohistochemical localization of delta-and mu-opioid receptors in primate spinal cord. Neuroreport 1995; 6: 1025-1028.
96. Schäfer MK, Bette M, Romeo H, Schwaeble W, Weihe E: Localization of kappa-opioid receptor mRNA in neuronal subpopulations of rat sensory ganglia and spinal cord. Neurosci Lett 1994; 167: 137-140.
97. Zhang Y, Pan YX, Kolesnikov Y, Pasternak GW: Immunohistochemical labeling of the mu opioid receptor carboxy terminal splice variant mMOR-1B4 in the mouse central nervous system. Brain Res 2006; 1099: 33-43. (Pubitemid 44080086)
98. Ray SB, Wadhwa S: Expression of mu-opioid receptors in developing rat spinal cord: An autoradiographic study. Indian J Exp Biol 2004; 42: 533-537. (Pubitemid 38642125)
99. Abbadie C, Pasternak GW, Aicher SA: Presynaptic localization of the carboxy-terminus epitopes of the opioid receptor splice variants MOR-1C and MOR-1D in the superficial laminae of the rat spinal cord. Neuroscience 2001; 106: 833-842. (Pubitemid 33000187)
100. Ray SB, Wadhwa S: Mu opioid receptors in developing human spinal cord. J Anat 1999; 195: 11-18. (Pubitemid 29378190)
101. Ding YQ, Kaneko T, Nomura S, Mizuno N: Immunohistochemical localization of muopioid receptors in the central nervous system of the rat. J Comp Neurol 1996; 367: 375-402. (Pubitemid 26107126)
102. Abbadie C, Lombard MC, Besson JM, Trafton JA, Basbaum AI: Mu and delta opioid receptor-like immunoreactivity in the cervical spinal cord of the rat after dorsal rhizotomy or neonatal capsaicin: An analysis of pre-and postsynaptic receptor distributions. Brain Res 2002; 930: 150-162. (Pubitemid 34195638)
103. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, Kieffer BL, Basbaum AI: Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009; 137: 1148-1159.
104. Bi J, Tsai NP, Lin YP, Loh HH, Wei LN: Axonal mRNA transport and localized translational regulation ofα-opioid receptor in primary neurons of dorsal root ganglia. Proc Natl Acad Sci USA 2006; 103: 19919-19924. (Pubitemid 46037531)
105. Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, Overland AC, Vanderah TW, Spencer RH: Peripheral mechanisms of pain and analgesia. Brain Res Rev 2009; 60: 90-113.
106. Faull RL, Villiger JW: Opiate receptors in the human spinal cord: A detailed anatomical study comparing the autoradiographic localization of [ 3 H]diprenorphine binding sites with the laminar pattern of substance P, myelin and nissl staining. Neuroscience 1987; 20: 395-407. (Pubitemid 17048703)
107. von Spiczak S, Whone AL, Hammers A, Asselin MC, Turkheimer F, Tings T, Happe S, Paulus W, Trenkwalder C, Brooks DJ: The role of opioids in restless legs syndrome: An [ 11 C]diprenorphine PET study. Brain 2005; 128: 906-917. (Pubitemid 40516927)
108. Walters AS: Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome. Sleep Med 2002; 3: 301-304.
109. Barriére G, Cazalets JR, Bioulac B, Tison F, Ghorayeb I: The restless legs syndrome. Prog Neurobiol 2005; 77: 139-165. (Pubitemid 41677621)
110. Sosnowski M, Stevens CW, Yaksh TL: Assessment of the role of A1/A2 adenosine receptors mediating the purine antinociception, motor and autonomic function in the rat spinal cord. J Pharmacol Exp Ther 1989; 250: 915-922. (Pubitemid 19246701)
111. Aoyama S, Kase H, Borrelli E: Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000; 20: 5848-5852. (Pubitemid 30636915)
112. Choca JI, Proudfit HK, Green RD: Identification of A1 and A2 adenosine receptors in the rat spinal cord. J Pharmacol Exp Ther 1987; 242: 905-910. (Pubitemid 17156530)
113. Lee HG, Kim WM, Choi JI, Yoon MH: Roles of adenosine receptor subtypes on the antinociceptive effect of sildenafil in rat spinal cord. Neurosci Lett 2010; 480: 182-185.
114. Reppert SM, Weaver DR, Stehle JH, Rivkees SA: Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol 1991; 5: 1037-1048.
115. Sumida T, Smith MA, Maehara Y, Collins JG, Kitahata LM: Spinal R-phenyl-isopropyl adenosine inhibits spinal dorsal horn neurons responding to noxious heat stimulation in the absence and presence of sensitization. Pain 1998; 74: 307-313. (Pubitemid 28081617)
116. Yoon MH, Choi JI, Jeong SW: Spinal gabapentin and antinociception: Mechanisms of action. J Korean Med Sci 2003; 18: 255-261. (Pubitemid 38011294)
117. Choca JI, Green RD, Proudfit HK: Adenosine A1 and A2 receptors of the substantia gelatinosa are located predominantly on intrinsic neurons: An autoradiography study. J Pharmacol Exp Ther 1988; 247: 757-764.
118. Lao LJ, Kawasaki Y, Yang K, Fujita T, Kumamoto E: Modulation by adenosine of Adelta and C primary-afferent glutamatergic transmission in adult rat substantia gelatinosa neurons. Neuroscience 2004; 125: 221-231. (Pubitemid 38402175)
119. Lao LJ, Kumamoto E, Luo C, Furue H, Yoshimura M: Adenosine inhibits excitatory transmission to substantia gelatinosa neurons of the adult rat spinal cord through the activation of presynaptic A 1 adenosine receptor. Pain 2001; 94: 315-324. (Pubitemid 33145401)
120. Schulte G, Robertson B, Fredholm BB, De-Lander GE, Shortland P, Molander C: Distribution of antinociceptive adenosine A 1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations. Neuroscience 2003; 121: 907-916. (Pubitemid 37324590)
121. Tian L, Ji G, Wang C, Bai X, Lu Y, Xiong L: Excitatory synaptic transmission in the spinal substantia gelatinosa is under an inhibitory tone of endogenous adenosine. Neurosci Lett 2010; 477: 28-32.
122. Wu L, Li H, Li YQ: Adenosine suppresses the response of neurons to GABA in the superficial laminae of the rat spinal dorsal horn. Neuroscience 2003; 119: 145-154. (Pubitemid 36577418)
123. Guntz E, Dumont H, Pastijn E, d'Exaerde Ade K, Azdad K, Sosnowski M, Schiffmann SN, Gall D: Expression of adenosine A 2A receptors in the rat lumbar spinal cord and implications in the modulation of N -methyl-d-aspartate receptor currents. Anesth Analg 2008; 106: 1882-1889.
124. Weaver DR: A1-adenosine receptor gene expression in fetal rat brain. Brain Res Dev Brain Res 1996; 94: 205-223. (Pubitemid 26292265)
125. Brooke RE, Deuchars J, Deuchars SA: Input-specific modulation of neurotransmitter release in the lateral horn of the spinal cord via adenosine receptors. J Neurosci 2004; 24: 127-137. (Pubitemid 38181678)
126. Peng SC, Ho CM, Ho ST, Tsai SK, Su CK: The role of intraspinal adenosine A 1 receptors in sympathetic regulation. Eur J Pharmacol 2004; 492: 49-55.
127. Sawynok J, Sweeney MI, White TD: Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br J Pharmacol 1986; 88: 923-930. (Pubitemid 16013101)
128. Horiuchi H, Ogata T, Morino T, Yamamoto H: Adenosine A1 receptor agonists reduce hyperalgesia after spinal cord injury in rats. Spinal Cord 2010; 48: 685-690.
129. Bura SA, Nadal X, Ledent C, Maldonado R, Valverde O: A 2A adenosine receptor regulates glia proliferation and pain after peripheral nerve injury. Pain 2008; 140: 95-103.
130. Thorpe AJ, Offord J: The alpha2-delta protein: An auxiliary subunit of voltage-dependent calcium channels as a recognized drug target. Curr Opin Investig Drugs 2010; 11: 761-770.
131. Bertrand S, Ng GY, Purisai MG, Wolfe SE, Severidt MW, Nouel D, Robitaille R, Low MJ, O'Neill GP, Metters K, Lacaille JC, Chronwall BM, Morris SJ: The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels. J Pharmacol Exp Ther 2001; 298: 15-24. (Pubitemid 32574505)
132. Parker DA, Ong J, Marino V, Kerr DI: Gabapentin activates presynaptic GABAB heteroreceptors in rat cortical slices. Eur J Pharmacol 2004; 495: 137-143. (Pubitemid 38891870)
133. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M, Trimble L, Bateman K, Alder L, Smith A, McKernan R, Metters K, O'Neill GP, Lacaille JC, Hebert TE: Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol 2001; 59: 144-152. (Pubitemid 32043096)
134. Taylor CP, Angelotti T, Fauman E: Pharmacology and mechanism of action of pregabalin: The calcium channel α 2δ (alpha2 -delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73: 137-150. (Pubitemid 46329329)
135. Cheng JK, Lee SZ, Yang JR, Wang CH, Liao YY, Chen CC, Chiou LC: Does gabapentin act as an agonist at native GABA(B) receptors? J Biomed Sci 2004; 11: 346-355.
136. Jensen AA, Mosbacher J, Elg S, Lingenhoehl K, Lohmann T, Johansen TN, Abrahamsen B, Mattsson JP, Lehmann A, Bettler B, Brauner-Osborne H: The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Mol Pharmacol 2002; 61: 1377-1384. (Pubitemid 34575748)
137. Lanneau C, Green A, Hirst WD, Wise A, Brown JT, Donnier E, Charles KJ, Wood M, Davies CH, Pangalos MN: Gabapentin is not a GABAB receptor agonist. Neuropharmacology 2001; 41: 965-975. (Pubitemid 34024992)
138. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the α 2δ ligand gabapentin. Proc Natl Acad Sci USA 2008; 105: 3628-3633. (Pubitemid 351723603)
139. Alden KJ, García J: Differential effect of gabapentin on neuronal and muscle calcium currents. J Pharmacol Exp Ther 2001; 297: 727-735. (Pubitemid 32378006)
140. Joshi I, Taylor CP: Pregabalin action at a model synapse: Binding to presynaptic calcium channel α 2-δ subunit reduces neurotransmission in mice. Eur J Pharmacol 2006; 553: 82-88. (Pubitemid 44779589)
141. 2+ channel α 2δ ligands: Novel modulators of neurotransmission. Trends Pharmacol Sci 2007; 28: 75-82. (Pubitemid 46161838)
142. Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, Kadurin I, Sri Ranjan Y, Fernandez-Alacid L, Millar NS, Dickenson AH, Lujan R, Dolphin AC: The increased trafficking of the calcium channel subunit α 2δ -1 to presynaptic terminals in neuropathic pain is inhibited by the α 2δ ligand pregabalin. J Neurosci 2009; 29: 4076-4088.
143. 2+ channelβ 4 subunit confers specificity for gabapentin inhibition of Ca v 2.1 trafficking. Mol Pharmacol 2008; 74: 904-912.
144. Taylor CP, Garrido R: Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha 2 -delta ( α 2-δ ) type 1 protein. Neuroscience 2008; 155: 510-521.
145. Cole RL, Lechner SM, Williams ME, Prodanovich P, Bleicher L, Varney MA, Gu G: Differential distribution of voltage-gated calcium channel alpha-2 delta ( α 2δ ) subunit mRNA-containing cells in the rat central nervous system and the dorsal root ganglia. J Comp Neurol 2005; 491: 246-269. (Pubitemid 41324594)
146. Li CY, Song YH, Higuera ES, Luo ZD: Spinal dorsal horn calcium channel α 2δ -1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 2004; 24: 8494-8499. (Pubitemid 39313772)
147. Li YN, Li YC, Kuramoto H, Liu ZR, Kawate T, Atsumi S, Deng YC, Huang YG: Immunohistochemical demonstration of the calcium channelα 2 subunit in the
148. Newton RA, Bingham S, Case PC, Sanger GJ, Lawson SN: Dorsal root ganglion neurons show increased expression of the calcium channel α 2δ -1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 2001; 95: 1-8. (Pubitemid 33000358)
149. Yusaf SP, Goodman J, Pinnock RD, Dixon AK, Lee K: Expression of voltage-gated calcium channel subunits in rat dorsal root ganglion neurons. Neurosci Lett 2001; 311: 137-141. (Pubitemid 32900624)
150. Rabchevsky AG, Patel SP, Duale H, Lyttle TS, O'Dell CR, Kitzman PH: Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury. Spinal Cord 2011; 49: 99-105.
151. Han DW, Kweon TD, Lee JS, Lee YW: Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain. Yonsei Med J 2007; 48: 41-47. (Pubitemid 46403632)
152. Ivanov SV, Ward JM, Tessarollo L, Mc-Areavey D, Sachdev V, Fananapazir L, Banks MK, Morris N, Djurickovic D, Devor-Henneman DE, Wei MH, Alvord GW, Gao B, Richardson JA, Minna JD, Rogawski MA, Lerman MI: Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol 2004; 165: 1007-1018. (Pubitemid 39129306)
153. Park S, Ahn ES, Han DW, Lee JH, Min KT, Kim H, Hong YW: Pregabalin and gabapentin inhibit substance P-induced NF-κ B activation in neuroblastoma and glioma cells. J Cell Biochem 2008; 105: 414-423.
154. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, Chakraborty C, Mulinyawe SB, Annis DS, Huberman AD, Green EM, Lawler J, Dolmetsch R, Garcia KC, Smith SJ, Luo ZD, Rosenthal A, Mosher DF, Barres BA: Gabapentin receptor α 2δ -1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009; 139: 380-392.
155. Rahman W, Bauer CS, Bannister K, Vonsy JL, Dolphin AC, Dickenson AH: Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Mol Pain 2009; 5: 45.
156. Takeuchi Y, Takasu K, Ono H, Tanabe M: Pregabalin, S -(+)-3-isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology 2007; 53: 842-853. (Pubitemid 350018824)
157. Tanabe M, Takasu K, Kasuya N, Shimizu S, Honda M, Ono H: Role of descending noradrenergic system and spinalα 2-adrenergic receptors in the effects of gabapentin on thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol 2005; 144: 703-714. (Pubitemid 40445619)
158. Tanabe M, Takasu K, Takeuchi Y, Ono H: Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury. J Neurosci Res 2008; 86: 3258-3264.